On Dec 12, 2024, the US Food and Drug Administration (FDA) approved crinecerfont for adults and paediatric patients with ...

For patients with active lupus nephritis, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody plus standard therapy is more efficacious for providing a complete renal response than ...

24 February 2025 US pharma giant Pfizer has ended all development and commercialization activities relating to fidanacogene elaparvovec, a hemophilia B gene therapy marketed as Beqvez in the USA and ...

Neurocrine's pipeline represents a critical component of its future growth strategy. The company is awaiting FDA decisions on crinecerfont for congenital adrenal hyperplasia (CAH), with PDUFA dates ...

The company’s Crinecerfont recently obtained Breakthrough Therapy designation for congenital adrenal hyperplasia (CAH).

Its flagship product, Ingrezza (valbenazine), is for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease. The company’s Crinecerfont recently obtained Breakthrough ...

The company’s Crinecerfont recently obtained Breakthrough Therapy designation for congenital adrenal hyperplasia (CAH). In addition to Ingrezza, Neurocrine’s diverse portfolio contains other ...

The company’s Crinecerfont recently obtained Breakthrough Therapy designation for congenital adrenal hyperplasia (CAH). In addition to Ingrezza, Neurocrine’s diverse portfolio contains other ...